Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|February 20, 2025
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trialHervé Bonnefoi, Florence Lerebours, Marina Pulido, et al.
Cancers|September 9, 2023
Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three DecadesMaud Toulmonde, Derek Dinart, Mehdi Brahmi, et al.
Investigational New Drugs|June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trialsJean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Therapeutic Advances in Medical Oncology|March 3, 2022
Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME databaseMarcela Carausu, Matthieu Carton, Luc Cabel, et al.
The Lancet. Oncology|August 10, 2024
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trialJean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Nature|July 17, 2019
Author Correction: Genomic characterization of metastatic breast cancersFrançois Bertucci, Charlotte K Y Ng, Anne Patsouris, et al.
Nature|May 24, 2019
Genomic characterization of metastatic breast cancersFrançois Bertucci, Charlotte K Y Ng, Anne Patsouris, et al.
Cell Reports. Medicine|May 23, 2024
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTsClémence Henon, Julien Vibert, Thomas Eychenne, et al.
Nature Medicine|January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trialThomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Pageof 5